The updated FAQ page.
I see it was posted at reddit/livimmune but wasn't sure it was here. The investor FAQ page was modified a few days ago.
I had to crawl the wayback machine to see the difference; 3rd objective now partnerships to advance the cause.
Was (June 26):
What are the current clinical objectives of the Company?
1. Continue the Phase 2 (CLOVER) study of leronlimab in patients with relapsed/refractory micro-satellite stable colorectal cancer;
2. Conduct additional studies exploring leronlimab and its therapeutic potential in other solid-tumor oncology indications, including but not limited to metastatic Triple-Negative Breast Cancer; and
3. Continue our work researching and developing a new or modified long-acting version of leronlimab.
Is:
What are the current clinical objectives of the Company?
1. Complete our Phase 2 study of leronlimab in patients with relapsed/refractory micro-satellite stable colorectal cancer, also known as the CLOVER study;
2, Conduct additional studies exploring leronlimab and its therapeutic potential in other solid-tumor oncology indications, including but not limited to metastatic triple negative breast cancer; and
3. Pursue strategic partnerships that will fund, advance, and/or expedite clinical development and regulatory progress towards the prospective commercialization of leronlimab.
Reminder of what they posted on LI 3 weeks ago:
Over the coming weeks, we’ll also be making updates to our website designed to provide a clearer look at our current strategy, development programs, and the continued scientific and clinical progress of leronlimab.
Thus far, other than scintillating, but good to see new objective 3 now acknowledged publicly.
I see it was posted at reddit/livimmune but wasn't sure it was here. The investor FAQ page was modified a few days ago.
I had to crawl the wayback machine to see the difference; 3rd objective now partnerships to advance the cause.
Was (June 26):
What are the current clinical objectives of the Company?
1. Continue the Phase 2 (CLOVER) study of leronlimab in patients with relapsed/refractory micro-satellite stable colorectal cancer;
2. Conduct additional studies exploring leronlimab and its therapeutic potential in other solid-tumor oncology indications, including but not limited to metastatic Triple-Negative Breast Cancer; and
3. Continue our work researching and developing a new or modified long-acting version of leronlimab.
Is:
What are the current clinical objectives of the Company?
1. Complete our Phase 2 study of leronlimab in patients with relapsed/refractory micro-satellite stable colorectal cancer, also known as the CLOVER study;
2, Conduct additional studies exploring leronlimab and its therapeutic potential in other solid-tumor oncology indications, including but not limited to metastatic triple negative breast cancer; and
3. Pursue strategic partnerships that will fund, advance, and/or expedite clinical development and regulatory progress towards the prospective commercialization of leronlimab.
Reminder of what they posted on LI 3 weeks ago:
Over the coming weeks, we’ll also be making updates to our website designed to provide a clearer look at our current strategy, development programs, and the continued scientific and clinical progress of leronlimab.
Thus far, other than scintillating, but good to see new objective 3 now acknowledged publicly.
4
